MedTrace Logo

Prevalence of Mast Cell Activation Syndrome in Patients With EDS With Digestive Disorders

NCT05382169 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 30

Last updated 2023-01-11

No results posted yet for this study

Summary

The aim of the study is to confirm the association between hypermobile Ehlers Danlos syndrome (hEDS) and mast cell activation syndrome (MCAS) in patients with digestive disorders managed in allergology departments.

Conditions

  • Ehlers Danlos Hypermobile Syndrome

Interventions

OTHER

Determine the presence of mast cell activation syndrome

Mast cell activation syndrome will be confirmed if the following three conditions are met (according to Valent et al, 2012) : * At least two clinical signs compatible with MAS before the first consultation (V1) * Improvement of symptoms on antihistamines within 2 months of initiation of treatment * Significant increase in tryptase during crisis Mast cell activation syndrome will be possible if : * At least two clinical signs consistent with MAS before the first consultation (V1) * Improvement of symptoms with antihistamines within 2 months of initiation of treatment * No significant increase in tryptase during crisis In all other cases, mast cell activation syndrome is unlikely.

Sponsors & Collaborators

  • Lille Catholic University

    lead OTHER

Principal Investigators

  • Juliette CARON, Md · Lille Catholic University

Eligibility

Min Age
14 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-09-28
Primary Completion
2025-01-31
Completion
2026-03-31

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05382169 on ClinicalTrials.gov